U.S. healthcare stocks generally turned in a lackluster performancein 1996, according to the results of Annual Healthcare IndustryReport, a year-end survey issued this week by WDI Capital Marketsof Hilton Head, SC. Overall, healthcare stocks were up a
U.S. healthcare stocks generally turned in a lackluster performancein 1996, according to the results of Annual Healthcare IndustryReport, a year-end survey issued this week by WDI Capital Marketsof Hilton Head, SC. Overall, healthcare stocks were up a meager2.7% in 1996, compared with growth of 40% in 1995. The industrywas down 4.7% in 1994 and 9.4% in 1993.
Within medical imaging, the imaging services segment saw its sharesgrow 43.5% for the year, a performance that led all healthcaresegments but was still down several points from 1995's hefty growthof 52%. The segment was driven by growth in shares of Health Images,which gained 129%; Alliance Imaging, which grew 105%; MedicalResources, up 103%; and SMT Health Services, up 95%.
The imaging devices segment ticked up a mere 4.3%, compared withgrowth of 75.9% in 1995, according to the WDI survey. Gains of97% by both Acuson and ADAC Laboratories were offset by a 47%decline at Elscint (including a 5-for-1 reverse stock split),a 41% drop in Fischer Imaging shares, and a 43% decline in Norland'sstock. Other firms whose shares posted gains in 1996 include OECMedical, up 54%; Lunar, up 27%; and Hologic, up 21%.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.